Guggenheim initiated coverage of Icosavax with a Buy rating and $28 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ICVX:
- Icosavax reports Q3 EPS (44c), consensus (57c)
- Icosavax, Inc. (ICVX) Q3 Earnings Cheat Sheet
- Icosavax to Participate in the Jefferies London Healthcare Conference
- Icosavax to Participate in the Guggenheim Healthcare Talks 5th Annual Inflammation, Neurology & Immunology (INI) Conference
- Icosavax to Participate in the Cantor Fitzgerald Global Healthcare Conference 2023